South Korea has long been one of Asia’s most sophisticated pharmaceutical regulatory environments. The Ministry of Food and Drug Safety (MFDS) has built a regulatory framework that draws from both US and European models, operates with genuine scientific rigour, and has, over the past decade, progressively aligned with ICH guidelines across quality, safety, efficacy, and multidisciplinary topic areas. For pharmaceutical companies targeting the Korean market, currently valued at over USD 30 billion and growing, MFDS registration is a substantive regulatory undertaking that requires preparation.
2026 has brought meaningful changes. Regulatory reforms in clinical data requirements, the expansion of Korea’s International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) alignment work, updates to the Biopharmaceutical Product Approval Framework, and MFDS’s revised approach to foreign clinical data have reshaped the registration environment in ways that both complicate and, for well-prepared sponsors simplify the path to marketing authorisation.
Structural Overview of MFDS Regulatory Framework
The Ministry of Food and Drug Safety (MFDS) is the primary regulatory authority for pharmaceuticals in South Korea, operating under the Pharmaceutical Affairs Act (약사법) and its subordinate regulations. MFDS’s pharmaceutical review functions are primarily executed through the National Institute of Food and Drug Safety Evaluation (NIFDS), which conducts scientific assessment of drug registration applications.
Korea’s pharmaceutical regulatory framework operates on a marketing authorisation model broadly consistent with the EU approach. Products are classified as new drugs (신약), new combination drugs, new formulations, generic drugs, and biosimilars, each with distinct documentation requirements and review processes.
Korea is a full ICH member (joining in 2016), and MFDS has implemented ICH E, Q, S, and M guidelines progressively since then. CTD format is standard for all new drug applications. MFDS accepts Module 2 CTD summaries in either Korean or English, with Module 1 Korean regulatory documents submitted in Korean.
Key Changes in MFDS Drug Registration for 2026
Revised Approach to Foreign Clinical Data Acceptability
One of the most significant ongoing shifts in Korean drug registration has been MFDS’s evolving approach to the acceptability of foreign clinical data for innovative medicines. Korea historically required domestic clinical studies (bridging studies or Phase 3 local trials) as a condition of registration for many new drugs, justified by the perceived need to demonstrate product safety and efficacy in Korean patients specifically.
The ICH E5 guideline which governs the acceptability of foreign clinical data, has been progressively embedded in MFDS’s review approach, but implementation has not always been consistent. In 2025-2026, MFDS has taken a more explicitly codified position on foreign data acceptability, aligned with its international partners’ approach:
- Multinational clinical trial data from ICH-region studies is accepted as the primary evidence base for innovative medicine applications
- Korean bridging data (typically pharmacokinetic bridging studies, ethnic sensitivity assessments, and limited domestic safety data) is required where the disease population or pharmacogenomic factors relevant to Korean patients differ materially from the multinational trial population
- MFDS has clarified guidance on when a full Korean Phase 3 study is required (generally limited to cases where significant population-level differences in disease characteristics or treatment response are expected, not as a universal requirement)
For international sponsors with completed multinational Phase 3 trials, this clarification meaningfully reduces the additional clinical development burden for Korean registration. The strategic implication is that Korean regulatory services timelines and clinical costs for innovative products are now more comparable to those of other major markets, provided the sponsor accurately characterises the ethnic and pharmacogenomic considerations and addresses them appropriately in the submission.
Expansion of the Conditional Approval Pathway
MFDS has operated a conditional approval mechanism for medicines addressing serious or life-threatening conditions with unmet medical need, broadly analogous to the FDA’s Accelerated Approval and EMA’s Conditional Marketing Authorisation. The 2025-2026 framework has expanded the scope of conditions eligible for conditional approval and provided more detailed guidance on the post-market commitments required to convert conditional approval to full marketing authorisation.
Under the revised framework, conditional approval candidates include:
- Medicines for conditions with no existing approved treatment in Korea
- Medicines for serious conditions where the clinical data package demonstrates a favourable benefit-risk profile on surrogate endpoints reasonably likely to predict clinical benefit
- Products already conditionally or fully approved in the US, EU, or Japan for the same indication (with MFDS review of the foreign approval basis)
The post-market commitment framework for conditional approvals has been clarified: MFDS now specifies that sponsors must submit a time-bound plan for confirmatory study completion, with defined milestones for interim analysis and final report submission. Conditional approvals that do not meet agreed milestones are subject to suspension or revocation.
Biosimilar Registration Framework Updates
South Korea has a substantial and growing domestic biologics and biosimilar industry, and MFDS has invested significantly in developing a rigorous biosimilar regulatory framework. In 2026, MFDS updated its biosimilar guidelines to more closely align with EMA’s stepwise comparability approach and ICH Q11 principles for biological characterisation.
Key updates include:
- More detailed guidance on the structural and functional comparability studies required in the analytical similarity assessment
- Revised requirements for clinical pharmacokinetics and pharmacodynamics data in biosimilar applications
- Clarification of the conditions under which clinical efficacy studies may be waived for biosimilars with robust analytical similarity packages
- Updated guidance on extrapolation of biosimilar indications where the reference product is approved in multiple indications
For international biosimilar developers, Korea’s alignment with EMA’s methodological approach means that biosimilar programmes designed to EMA standards are increasingly compatible with MFDS registration requirements — reducing the marginal cost of Korean registration for companies already pursuing EU biosimilar approval.
Digital Health and Software as a Medical Device (SaMD) Integration
MFDS has been among the Asia-Pacific’s most active regulators in developing frameworks for digital therapeutic and Software as a Medical Device (SaMD) regulation. While this is technically a medical device consideration rather than drug registration per se, the intersection of digital therapeutics with pharmaceutical products, including combination drug-device products and prescription digital therapeutics, has created new regulatory pathways under MFDS oversight in 2026.
Companies developing drug-device combinations or pharmaceutical products with companion diagnostic or digital monitoring components should engage with MFDS’s combined regulatory pathway early, as the interface between MFDS’s drug and device review divisions requires explicit coordination.
Step by Step Korean Drug Registration Process
Pre-Submission Consultation
MFDS’s pre-consultation system (사전검토) allows sponsors to engage with NIFDS reviewers before formal submission to discuss data packages, application strategy, and potential deficiency areas. Pre-consultation is not mandatory, but for innovative medicines, particularly biologicals, combination products, and products with complex clinical data packages, it is strongly advisable.
MFDS pre-consultation requests must be submitted in Korean (with supporting documents acceptable in English), and the turnaround for consultation responses is typically 30 to 60 calendar days. The investment in pre-consultation routinely pays back in reduced review queries.
Application Submission Through EZDRUG
Formal applications to MFDS are submitted through the EZDRUG electronic submission system (의약품안전나라). The system has been progressively upgraded in recent years, and as of 2026, it supports full eCTD submission for both domestic and foreign applicants. MFDS accepts Module 1 Korean-language documents through EZDRUG, with Modules 2-5 in CTD format acceptable in English (with specified sections in Korean).
Module 1 Korean-specific documents include the Korean-language prescribing information (PI/SmPC equivalent), the Korean packaging and labelling draft, and the Korean administrative section with applicant and manufacturing information.
Review Timeline and MFDS Targets
MFDS targets the following review timelines for drug registration applications:
- New drugs (innovative medicines): 320 working days from acceptance
- New formulations and combinations: 200 working days
- Generic drugs: 120 working days
- Priority review (Rare disease, conditional approval pathway): 180 working days
These are internal target timelines. Clock stops for additional information requests (보완 요청) are common, particularly in Module 3 quality sections for complex products and in Module 5 clinical sections where ethnic bridging data questions arise. Total elapsed calendar time from submission to approval for innovative medicines has typically ranged from 18 to 30 months.
Pharmacovigilance Obligations Under MFDS Registration
Korea’s pharmacovigilance framework has been substantially developed in recent years, with MFDS’s pharmacovigilance division (의약품안전평가과) progressively aligning with ICH E2 series guidelines.
Korean Adverse Event Reporting Timelines
Holders of Korean marketing authorisations must report serious unexpected adverse drug reactions to MFDS within 15 calendar days. Periodic safety reports, Korea’s equivalent of the PSUR/PBRER, are submitted on schedules aligned with the marketing authorisation’s approval history, with the submission timing and international birth date (IBD) used to align Korean PSUR schedules with global reporting timelines.
Korea’s National Pharmacovigilance Centre (NPC) operates a spontaneous reporting database, and MFDS analyses signal data independently, with the capacity to initiate safety reviews and require label updates outside the PSUR cycle.
Risk Management Plans for Korean Registration
MFDS requires Risk Management Plans for innovative medicines, biosimilars, and products with identified safety risks. The Korean RMP format follows a structure broadly aligned with the EU RMP, with a Korean-specific annex addressing local post-market safety activities, Korean pharmacoepidemiological data, and any Korean-specific risk minimisation measures.
Companies that have EU RMPs in place should note that adaptation to Korean requirements, while not wholesale redrafting, involves substantive localisation work, particularly for the Korean-specific annex and the integration of Korean safety data sources.
Conclusion
MFDS drug registration in 2026 is more internationally aligned than at any point in its history, with clearer positions on foreign clinical data acceptability, an expanded conditional approval pathway, and a biosimilar framework that increasingly mirrors EMA standards. These changes reward international pharmaceutical companies that invest in rigorous preparation, Korean-specific regulatory planning, and proactive pre-submission engagement with NIFDS. The Korean market’s commercial significance and its growing influence on regional regulatory frameworks makes it a priority market for any serious Asia-Pacific pharmaceutical strategy.
DDReg has extensive experience supporting international pharmaceutical and biopharmaceutical companies with MFDS drug registration, including innovative medicine applications, biosimilar submissions, and conditional approval strategy. From Korean-language regulatory documentation preparation and eCTD compilation to pre-consultation support, RMP localisation, and pharmacovigilance programme establishment, DDReg’s team provides specialist support calibrated to MFDS’s current regulatory expectations.